301331 恩威医药
2026/09 - 九个月2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)2.1344.8763.4717.6517.553
总资产报酬率 ROA (%)1.5013.4002.6396.2925.960
投入资产回报率 ROIC (%)1.7484.0183.0957.4307.280

边际利润分析
销售毛利率 (%)49.75649.51250.81551.25550.196
营业利润率 (%)4.3316.9236.11812.95611.842
息税前利润/营业总收入 (%)4.9007.0805.59212.08711.644
净利润/营业总收入 (%)3.9675.7674.61710.9939.804

收益指标分析
经营活动净收益/利润总额(%)71.29491.170104.86585.73986.845
价值变动净收益/利润总额(%)9.4951.3787.4853.6940.721
营业外收支净额/利润总额(%)10.5392.813-6.432-0.407-0.041

偿债能力分析
流动比率 (X)4.3532.1443.9933.7514.206
速动比率 (X)3.7151.9223.5083.2393.746
资产负债率 (%)28.41030.81629.70117.51917.999
带息债务/全部投入资本 (%)17.47615.27516.3310.2631.182
股东权益/带息债务 (%)462.583543.083501.22937,055.8828,176.952
股东权益/负债合计 (%)251.988224.504236.691470.820455.593
利息保障倍数 (X)83.393-164.772-35.711-14.804-60.142

营运能力分析
应收账款周转天数 (天)63.93152.37847.28443.88345.020
存货周转天数 (天)107.84085.751100.45399.708112.181